K W Mahaffey

Summary

Affiliation: Duke University Medical Center
Country: USA

Publications

  1. pmc Methods of creatine kinase-MB analysis to predict mortality in patients with myocardial infarction treated with reperfusion therapy
    Renato D Lopes
    Duke Clinical Research Institute, Duke University Medical Center, 2400 Pratt Street, Room 0311, Terrace Level, Box 3850, Durham, NC 27705, USA
    Trials 14:123. 2013
  2. doi request reprint Strategic lessons from the clinical event classification process for the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) trial
    Kenneth W Mahaffey
    Duke Clinical Research Institute, Durham, NC 27705, USA
    Contemp Clin Trials 32:178-87. 2011
  3. ncbi request reprint Low-molecular-weight heparins and glycoprotein IIb/IIIa inhibitors with percutaneous coronary intervention in acute coronary syndromes
    Rahul A Shimpi
    Duke Clinical Research Institute, 2400 Pratt Street, Room 0311, Terrace Level, Durham, NC, 27705, USA
    J Invasive Cardiol 15:460-5. 2003
  4. ncbi request reprint Effect of pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to fibrinolysis in acute myocardial infarction: the COMPlement inhibition in myocardial infarction treated with thromboLYtics (COMPLY) trial
    Kenneth W Mahaffey
    Duke Clinical Research Institute, Durham, NC 27715, USA
    Circulation 108:1176-83. 2003
  5. ncbi request reprint The anticoagulant therapy with bivalirudin to assist in the performance of percutaneous coronary intervention in patients with heparin-induced thrombocytopenia (ATBAT) study: main results
    Kenneth W Mahaffey
    Duke Clinical Research Institute, Durham, NC 27715, USA
    J Invasive Cardiol 15:611-6. 2003
  6. ncbi request reprint Characterization of myocardial infarction as an end point in two large trials of acute coronary syndromes
    Kenneth W Mahaffey
    Division of Cardiology and Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina 27715, USA
    Am J Cardiol 95:1404-8. 2005
  7. doi request reprint Obesity in patients with non-ST-segment elevation acute coronary syndromes: results from the SYNERGY trial
    Kenneth W Mahaffey
    Duke Clinical Research Institute, Durham, NC 27715, USA
    Int J Cardiol 139:123-33. 2010
  8. doi request reprint Integrating ancillary studies in a large clinical trial: the design and rationale of the APEX library
    Kenneth W Mahaffey
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27705, USA
    Contemp Clin Trials 29:887-95. 2008
  9. ncbi request reprint High-risk patients with acute coronary syndromes treated with low-molecular-weight or unfractionated heparin: outcomes at 6 months and 1 year in the SYNERGY trial
    Kenneth W Mahaffey
    Duke Clinical Research Institute, Durham, NC 27715, USA
    JAMA 294:2594-600. 2005
  10. pmc Prediction of one-year survival in high-risk patients with acute coronary syndromes: results from the SYNERGY trial
    Kenneth W Mahaffey
    Duke Clinical Research Institute, Durham, NC 27715, USA
    J Gen Intern Med 23:310-6. 2008

Collaborators

Detail Information

Publications99

  1. pmc Methods of creatine kinase-MB analysis to predict mortality in patients with myocardial infarction treated with reperfusion therapy
    Renato D Lopes
    Duke Clinical Research Institute, Duke University Medical Center, 2400 Pratt Street, Room 0311, Terrace Level, Box 3850, Durham, NC 27705, USA
    Trials 14:123. 2013
    ..We evaluated alternative approaches to quantifying infarct size using CK-MB values, and the relationship between infarct size and clinical outcomes...
  2. doi request reprint Strategic lessons from the clinical event classification process for the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) trial
    Kenneth W Mahaffey
    Duke Clinical Research Institute, Durham, NC 27705, USA
    Contemp Clin Trials 32:178-87. 2011
    ..Independent adjudication of clinical trial events is traditionally performed by physicians on a clinical event classification (CEC) committee...
  3. ncbi request reprint Low-molecular-weight heparins and glycoprotein IIb/IIIa inhibitors with percutaneous coronary intervention in acute coronary syndromes
    Rahul A Shimpi
    Duke Clinical Research Institute, 2400 Pratt Street, Room 0311, Terrace Level, Durham, NC, 27705, USA
    J Invasive Cardiol 15:460-5. 2003
  4. ncbi request reprint Effect of pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to fibrinolysis in acute myocardial infarction: the COMPlement inhibition in myocardial infarction treated with thromboLYtics (COMPLY) trial
    Kenneth W Mahaffey
    Duke Clinical Research Institute, Durham, NC 27715, USA
    Circulation 108:1176-83. 2003
    ..The COMPLY trial is reported here...
  5. ncbi request reprint The anticoagulant therapy with bivalirudin to assist in the performance of percutaneous coronary intervention in patients with heparin-induced thrombocytopenia (ATBAT) study: main results
    Kenneth W Mahaffey
    Duke Clinical Research Institute, Durham, NC 27715, USA
    J Invasive Cardiol 15:611-6. 2003
    ..Bivalirudin appeared safe and provided effective anticoagulation during PCI. These data, and extensive experience with bivalirudin in PCI, support its use in high-risk patients with HIT requiring PCI...
  6. ncbi request reprint Characterization of myocardial infarction as an end point in two large trials of acute coronary syndromes
    Kenneth W Mahaffey
    Division of Cardiology and Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina 27715, USA
    Am J Cardiol 95:1404-8. 2005
    ..All MI types were associated with worse short- and long-term outcomes. Characterization of the type of MI provides an opportunity for more informed interpretation of clinical trial results and improved planning for future trials...
  7. doi request reprint Obesity in patients with non-ST-segment elevation acute coronary syndromes: results from the SYNERGY trial
    Kenneth W Mahaffey
    Duke Clinical Research Institute, Durham, NC 27715, USA
    Int J Cardiol 139:123-33. 2010
    ....
  8. doi request reprint Integrating ancillary studies in a large clinical trial: the design and rationale of the APEX library
    Kenneth W Mahaffey
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27705, USA
    Contemp Clin Trials 29:887-95. 2008
    ..The operational paradigm of this effort should be considered in future investigations so that important advances in clinical care of disease can be realized efficiently...
  9. ncbi request reprint High-risk patients with acute coronary syndromes treated with low-molecular-weight or unfractionated heparin: outcomes at 6 months and 1 year in the SYNERGY trial
    Kenneth W Mahaffey
    Duke Clinical Research Institute, Durham, NC 27715, USA
    JAMA 294:2594-600. 2005
    ....
  10. pmc Prediction of one-year survival in high-risk patients with acute coronary syndromes: results from the SYNERGY trial
    Kenneth W Mahaffey
    Duke Clinical Research Institute, Durham, NC 27715, USA
    J Gen Intern Med 23:310-6. 2008
    ..Despite advances in pharmacologic therapy and invasive management strategies for patients with non-ST-segment elevation acute coronary syndromes (NSTE ACS), these patients still suffer substantial morbidity and mortality...
  11. ncbi request reprint Effect of pexelizumab on mortality in patients with acute myocardial infarction or undergoing coronary artery bypass surgery: a systematic overview
    Kenneth W Mahaffey
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27705, USA
    Am Heart J 152:291-6. 2006
    ....
  12. pmc Acute coronary syndromes: what have we learned about what we still need to know?
    Kenneth W Mahaffey
    Duke Clinical Research Institute, Durham, North Carolina 27705, USA
    Tex Heart Inst J 33:187-9. 2006
  13. ncbi request reprint Creatine kinase-MB elevation after coronary artery bypass grafting surgery in patients with non-ST-segment elevation acute coronary syndromes predict worse outcomes: results from four large clinical trials
    Kenneth W Mahaffey
    Duke Clinical Research Institute, PO Box 17969, Durham, NC 27715, USA, and Catholic University Hospital, Leuven, Belgium
    Eur Heart J 28:425-32. 2007
    ..To assess the significance of creatine kinase (CK)-MB elevations in outcomes of patients with non-ST-segment elevation acute coronary syndromes (NSTE ACS) who have undergone coronary artery bypass grafting (CABG) surgery...
  14. doi request reprint The impact of postrandomization crossover of therapy in acute coronary syndromes care
    Kenneth W Mahaffey
    Division of Cardiology and Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27715, USA
    Circ Cardiovasc Qual Outcomes 4:211-9. 2011
    ..Using SYNERGY as an example, we demonstrate the difficulty of evaluating the effect of postrandomization events in clinical trials and discuss possible methodology...
  15. doi request reprint Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial
    Kenneth W Mahaffey
    Duke Clinical Research Institute, Durham, NC 27715, USA
    Circulation 124:544-54. 2011
    ..045), with less effect of ticagrelor in North America than in the rest of the world...
  16. ncbi request reprint Adenosine as an adjunct to thrombolytic therapy for acute myocardial infarction: results of a multicenter, randomized, placebo-controlled trial: the Acute Myocardial Infarction STudy of ADenosine (AMISTAD) trial
    K W Mahaffey
    Duke Clinical Research Institute, Durham, North Carolina 27715, USA
    J Am Coll Cardiol 34:1711-20. 1999
    ..The Acute Myocardial Infarction STudy of ADenosine (AMISTAD) trial was designed to test the hypothesis that adenosine as an adjunct to thrombolysis would reduce myocardial infarct size...
  17. ncbi request reprint Stroke in patients with acute coronary syndromes: incidence and outcomes in the platelet glycoprotein IIb/IIIa in unstable angina. Receptor suppression using integrilin therapy (PURSUIT) trial. The PURSUIT Investigators
    K W Mahaffey
    Duke Clinical Research Institute, Durham, NC, USA
    Circulation 99:2371-7. 1999
    ..The incidence of stroke in patients with acute coronary syndromes has not been clearly defined because few trials in this patient population have been large enough to provide stable estimates of stroke rates...
  18. ncbi request reprint Misreporting of myocardial infarction end points: results of adjudication by a central clinical events committee in the PARAGON-B trial. Second Platelet IIb/IIIa Antagonist for the Reduction of Acute Coronary Syndrome Events in a Global Organization Netwo
    Kenneth W Mahaffey
    Duke Clinical Research Institute, Durham, NC 27715, USA
    Am Heart J 143:242-8. 2002
    ..We examined disagreement between investigator and clinical events committee (CEC) reporting of MIs in an international, randomized trial...
  19. ncbi request reprint Risk factors for in-hospital nonhemorrhagic stroke in patients with acute myocardial infarction treated with thrombolysis: results from GUSTO-I
    K W Mahaffey
    Duke Clinical Research Institute, Durham, North Carolina, USA
    Circulation 97:757-64. 1998
    ..Nonhemorrhagic stroke occurs in 0.1% to 1.3% of patients with acute myocardial infarction who are treated with thrombolysis, with substantial associated mortality and morbidity. Little is known about the risk factors for its occurrence...
  20. ncbi request reprint Anticoagulation for acute coronary syndromes and percutaneous coronary intervention in patients with heparin-induced thrombocytopenia
    K W Mahaffey
    Duke Clinical Research Institute, PO Box 17969, Durham, NC 27715, USA
    Curr Cardiol Rep 3:362-70. 2001
    ....
  21. ncbi request reprint Diabetic retinopathy should not be a contraindication to thrombolytic therapy for acute myocardial infarction: review of ocular hemorrhage incidence and location in the GUSTO-I trial. Global Utilization of Streptokinase and t-PA for Occluded Coronary Arte
    K W Mahaffey
    Department of Medicine, Duke University Medical Center, Durham, North Carolina, USA
    J Am Coll Cardiol 30:1606-10. 1997
    ..This study sought to evaluate the incidence of ocular hemorrhage in patients with and without diabetes after thrombolytic therapy for acute myocardial infarction...
  22. ncbi request reprint Clinical outcomes after detection of elevated cardiac enzymes in patients undergoing percutaneous intervention. IMPACT-II Investigators. Integrilin (eptifibatide) to Minimize Platelet Aggregation and Coronary Thrombosis-II
    B E Tardiff
    Duke Clinical Research Institute, Durham, North Carolina 27710, USA
    J Am Coll Cardiol 33:88-96. 1999
    ....
  23. ncbi request reprint Current perspectives on reperfusion therapy for acute ST-segment elevation myocardial infarction: integrating pharmacologic and mechanical reperfusion strategies
    Richard E Waters
    Duke Clinical Research Institute, Durham, NC 27705, USA
    Am Heart J 146:958-68. 2003
    ..Thus, as the reperfusion era continues to evolve, the ideal treatment strategy for patients with STEMI is being redefined to integrate pharmacologic and mechanical approaches to reperfusion...
  24. ncbi request reprint Association between minor elevations of creatine kinase-MB level and mortality in patients with acute coronary syndromes without ST-segment elevation. PURSUIT Steering Committee. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Usin
    J H Alexander
    Duke Clinical Research Institute, Durham, NC 27715, USA
    JAMA 283:347-53. 2000
    ..Controversy surrounds the diagnostic and prognostic importance of slightly elevated cardiac markers in patients with acute coronary syndromes without ST-segment elevation...
  25. ncbi request reprint Myonecrosis after revascularization procedures
    R M Califf
    Department of Anesthesiology, Duke University Medical Center, Durham, North Carolina, USA
    J Am Coll Cardiol 31:241-51. 1998
    ..In addition, tracking of enzyme levels in clinical trials is needed to determine whether interventions that reduce periprocedural enzyme elevation also improve mortality...
  26. ncbi request reprint Effects of stroke on medical resource use and costs in acute myocardial infarction. GUSTO I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries Study
    C Y Tung
    Duke Clinical Research Institute, Durham, NC, USA
    Circulation 99:370-6. 1999
    ..However, no data exist for the economic effect of stroke in the setting of acute MI (AMI). The purpose of this prospective study was to assess the effect of stroke on medical resource use and costs in AMI patients in the United States...
  27. ncbi request reprint Exploring the role of enoxaparin in the management of high-risk patients with non-ST-elevation acute coronary syndromes: the SYNERGY trial
    Kenneth W Mahaffey
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA
    Am Heart J 149:S81-90. 2005
    ..However, the critical trials comparing enoxaparin with UFH were conducted before the widespread use of early invasive management and the availability of clopidogrel and glycoprotein IIb/IIIa receptor antagonists...
  28. doi request reprint Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial
    John H Alexander
    Duke Clinical Research Institute, Duke University Medical Center, DUMC Box 3850, Durham, NC 27715, USA
    Circulation 119:2877-85. 2009
    ..After an acute coronary syndrome, patients remain at risk of recurrent events. Apixaban, an oral direct factor Xa inhibitor, is a novel anticoagulant that may reduce these events but also poses a risk of bleeding...
  29. doi request reprint Prevalence, predictors, and impact of conservative medical management for patients with non-ST-segment elevation acute coronary syndromes who have angiographically documented significant coronary disease
    Mark Y Chan
    Duke Clinical Research Institute, Durham, North Carolina, USA
    JACC Cardiovasc Interv 1:369-78. 2008
    ..We sought to characterize the utilization and impact of a conservative medical management strategy for patients with non-ST-segment elevation acute coronary syndromes (NSTE ACS) and significant coronary artery disease on early angiography...
  30. ncbi request reprint Creatine kinase-MB elevation after percutaneous coronary intervention predicts adverse outcomes in patients with acute coronary syndromes
    M T Roe
    Duke Clinical Research Institute, Durham, North Carolina, USA
    Eur Heart J 25:313-21. 2004
    ..To study the relationship between outcomes and peak creatine kinase (CK)-MB levels after percutaneous coronary intervention (PCI) in patients with non-ST-segment elevation acute coronary syndromes (NSTE ACS)...
  31. ncbi request reprint Cost-effectiveness of platelet glycoprotein IIb/IIIa inhibition with eptifibatide in patients with non-ST-elevation acute coronary syndromes
    D B Mark
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27710, USA
    Circulation 101:366-71. 2000
    ..In the PURSUIT trial, eptifibatide significantly reduced the 30-day incidence of death and myocardial infarction relative to placebo in 9461 patients with an acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction)...
  32. ncbi request reprint Coordinated series of studies to evaluate characteristics and mechanisms of acute coronary syndromes in high-risk patients randomly assigned to enoxaparin or unfractionated heparin: design and rationale of the SYNERGY Library
    John L Petersen
    Division of Cardiology and Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA
    Am Heart J 148:269-76. 2004
    ..It is hoped that the SYNERGY Library will serve as a model for future substudy design to maximize academic insight within the framework of a large-scale, multicenter trial...
  33. ncbi request reprint A randomized, placebo-controlled trial of enoxaparin after high-risk coronary stenting: the ATLAST trial
    W B Batchelor
    The Duke Clinical Research Institute, Durham, North Carolina, USA
    J Am Coll Cardiol 38:1608-13. 2001
    ..However, given its relative safety and potential to reduce the risk of subsequent infarction, a 14-day course of enoxaparin may be considered for carefully selected patients...
  34. ncbi request reprint Incidence and characteristics of stroke during 90-day follow-up in patients stabilized after an acute coronary syndrome
    Hassan Kassem-Moussa
    Duke Clinical Research Institute, Durham, NC 27715, USA
    Am Heart J 148:439-46. 2004
    ..Stroke is a rare but serious event that complicates the course of patients with acute coronary syndromes (ACS). The type, outcome, and risk factors of stroke occurring in stabilized patients with ACS have not been previously reported...
  35. ncbi request reprint Clinical use of enoxaparin in the management of non-ST segment elevation acute coronary syndromes
    John M Galla
    Duke Clinical Research Institute, Duke University Medical Center, 2400 Pratt Street, Durham, NC 27715, USA
    Expert Opin Pharmacother 6:1241-51. 2005
    ..These data support the role of enoxaparin as an anti-coagulant in patients with NSTE ACS...
  36. ncbi request reprint Shifting the open-artery hypothesis downstream: the quest for optimal reperfusion
    M T Roe
    Duke Clinical Research Institute, Durham, North Carolina 27715, USA
    J Am Coll Cardiol 37:9-18. 2001
    ..Thus, as the reperfusion era moves into the next millennium, the open-artery hypothesis is expected to shift downstream and guide efforts to further improve myocardial salvage and clinical outcomes after acute MI...
  37. ncbi request reprint Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-Segment elevation acute coronary syndromes: a systematic overview
    John L Petersen
    Duke Clinical Research Institute, Durham, NC 27715, USA
    JAMA 292:89-96. 2004
    ....
  38. ncbi request reprint Prognostic usefulness of white blood cell count and temperature in acute myocardial infarction (from the CARDINAL Trial)
    Manesh R Patel
    Division of Cardiology and Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina, USA
    Am J Cardiol 95:614-8. 2005
    ..Baseline and serial measurements of WBC counts and temperature were correlated with infarct size and clinical outcome...
  39. ncbi request reprint Low-molecular-weight heparin compared with unfractionated heparin for patients with non-ST-segment elevation acute coronary syndromes treated with glycoprotein IIb/IIIa inhibitors: results from the CRUSADE initiative
    Kanwar P Singh
    Division of Cardiology and Duke Clinical Research Institute, Durham, NC 27705, USA
    J Thromb Thrombolysis 21:211-20. 2006
    ..We sought to compare the efficacy and safety of these treatment strategies in a large contemporary population of patients with NSTE ACS...
  40. ncbi request reprint Elevated creatine kinase-MB with normal creatine kinase predicts worse outcomes in patients with acute coronary syndromes: results from 4 large clinical trials
    John M Galla
    Duke Clinical Research Institute, Durham, NC 27705, USA
    Am Heart J 151:16-24. 2006
    ..A concomitant goal was to contribute insight to the debate over how patients with NSTE ACS should be managed...
  41. ncbi request reprint Treatment and outcomes of patients with evolving myocardial infarction: experiences from the SYNERGY trial
    Chadwick D Miller
    Department of Emergency Medicine, Wake Forest University School of Medicine, Winston Salem, NC, USA
    Eur Heart J 28:1079-84. 2007
    ..We compared the initial treatment and clinical outcomes of patients presenting with evolving MI (EMI) with those presenting with MI...
  42. ncbi request reprint Troponin T and quantitative ST-segment depression offer complementary prognostic information in the risk stratification of acute coronary syndrome patients
    Padma Kaul
    Duke Clinical Research Institute, Duke University, Durham, North Carolina, USA
    J Am Coll Cardiol 41:371-80. 2003
    ....
  43. ncbi request reprint Racial differences among high-risk patients presenting with non-ST-segment elevation acute coronary syndromes (results from the SYNERGY trial)
    Melvin R Echols
    Duke Clinical Research Institute, Durham, North Carolina, USA
    Am J Cardiol 99:315-21. 2007
    ..African-American patients had significantly better adjusted 30-day outcomes but similar 6-month outcomes compared with white patients...
  44. ncbi request reprint Impact of perioperative myocardial infarction on angiographic and clinical outcomes following coronary artery bypass grafting (from PRoject of Ex-vivo Vein graft ENgineering via Transfection [PREVENT] IV)
    James M Yau
    Duke University Medical Center, Durham, North Carolina, USA
    Am J Cardiol 102:546-51. 2008
    ..Further research is needed into the prevention and treatment of perioperative MI in patients undergoing CABG...
  45. ncbi request reprint Risk factors for intracranial hemorrhage and nonhemorrhagic stroke after fibrinolytic therapy (from the GUSTO-i trial)
    David E Kandzari
    Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA
    Am J Cardiol 93:458-61. 2004
    ..4, 95% confidence interval 1.2 to 10.2). Because facial or head trauma may greatly influence treatment decisions, this risk factor should be incorporated into models designed to estimate the risks and benefits of fibrinolytic therapy...
  46. doi request reprint Warfarin use and outcomes in patients with atrial fibrillation complicating acute coronary syndromes
    Renato D Lopes
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA
    Am J Med 123:134-40. 2010
    ....
  47. ncbi request reprint Platelet glycoprotein IIb/IIIa receptor antagonists in non-ST segment elevation acute coronary syndromes: a review and guide to patient selection
    Brett D Atwater
    Duke Clinical Research Institute, Durham, North Carolina 27705, USA
    Drugs 65:313-24. 2005
    ....
  48. ncbi request reprint Efficacy and safety of the low-molecular weight heparin enoxaparin compared with unfractionated heparin across the acute coronary syndrome spectrum: a meta-analysis
    Sabina A Murphy
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, 350 Longwood Avenue, First Floor, Boston, MA 02115, USA
    Eur Heart J 28:2077-86. 2007
    ....
  49. ncbi request reprint Short- and long-term outcomes following atrial fibrillation in patients with acute coronary syndromes with or without ST-segment elevation
    R D Lopes
    Duke Clinical Research Institute, Duke University Medical Center, 2400 Pratt Street, Room 0311 Terrace Level, Durham, NC 27707, USA
    Heart 94:867-73. 2008
    ....
  50. ncbi request reprint Rivaroxaban, an oral direct factor Xa inhibitor
    Jonathan P Piccini
    Duke University Medical Center, Duke Clinical Research Institute, 2400 Pratt Street, 7581, Durham, NC 27705, USA
    Expert Opin Investig Drugs 17:925-37. 2008
    ..The drug may have its greatest impact in providing a much-needed and attractive alternative to warfarin. Further data (especially large Phase III trials) are required...
  51. doi request reprint Heparin-associated anti-Xa activity and platelet-derived prothrombotic and proinflammatory biomarkers in moderate to high-risk patients with acute coronary syndrome
    Richard C Becker
    Division of Cardiology Medicine, Duke University Medical Center, Duke Clinical Research Institute, Durham, NC 27715, USA
    J Thromb Thrombolysis 31:146-53. 2011
    ..Whether this potentially beneficial effect is direct or indirect and achieved, at least in part, through the release of endothelial cell-derived coagulation regulatory proteins will require further investigation...
  52. doi request reprint Evaluation of a new heparin agent in percutaneous coronary intervention: results of the phase 2 evaluation of M118 IN pErcutaNeous Coronary intErvention (EMINENCE) Trial
    Sunil V Rao
    Duke Clinical Research Institute, Durham, NC, USA
    Circulation 121:1713-21. 2010
    ..We performed a phase 2 randomized trial to evaluate the safety and feasibility of M118 in the setting of elective percutaneous coronary intervention...
  53. doi request reprint Influence of clinical trial participation on subsequent antithrombin use
    Bimal R Shah
    Duke Clinical Research Institute, Duke University Medical Center, 2400 Pratt Street, Durham, NC 27705, USA
    Clin Cardiol 33:E49-55. 2010
    ....
  54. doi request reprint Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study
    Richard C Becker
    Duke Clinical Research Institute, Durham, NC, USA
    Lancet 373:919-28. 2009
    ..We therefore assessed the tolerability and safety of SCH 530348-an oral platelet protease-activated receptor-1 antagonist...
  55. ncbi request reprint Oral factor Xa inhibitors for the prevention of stroke in atrial fibrillation
    Jonathan P Piccini
    Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina, USA
    Curr Opin Cardiol 25:312-20. 2010
    ..Consequently, much research has been focused on finding an alternative to warfarin. We review the potential alternatives in development and evaluate the current evidence concerning their safety and efficacy...
  56. doi request reprint Management of acute coronary syndromes in patients with renal dysfunction
    Chiara Melloni
    Division of Cardiology and Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina 27705, USA
    Curr Opin Cardiol 23:320-6. 2008
    ..Often, patients with chronic kidney disease are excluded from clinical trials, so in clinical practice physicians may not have definitive evidence to support treatment decisions...
  57. doi request reprint Outcomes in elderly patients with acute coronary syndromes randomized to enoxaparin vs. unfractionated heparin: results from the SYNERGY trial
    Renato D Lopes
    Duke Clinical Research Institute, Box 3850, 2400 Pratt Street, Room 311, Terrace Level, Durham, NC 27705, USA
    Eur Heart J 29:1827-33. 2008
    ..The SYNERGY database was used to study the influence of age on treatment outcomes with enoxaparin vs. unfractionated heparin (UFH) in patients with high-risk NSTE ACS...
  58. doi request reprint Platelet inhibition with cangrelor in patients undergoing PCI
    Robert A Harrington
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27705, USA
    N Engl J Med 361:2318-29. 2009
    ..This agent might have a role in the treatment of patients who require rapid, predictable, and profound but reversible platelet inhibition...
  59. ncbi request reprint Time to coronary angiography and outcomes among patients with high-risk non ST-segment elevation acute coronary syndromes: results from the SYNERGY trial
    Pierluigi Tricoci
    Duke Clinical Research Institute, 2400 Pratt St, Room 0311 Terrace Level, Durham, NC 27705, USA
    Circulation 116:2669-77. 2007
    ..We evaluated the relationship between time from hospital admission to coronary angiography and outcomes in high-risk patients with non-ST-segment-elevation acute coronary syndrome who underwent angiography within 48 hours of admission...
  60. ncbi request reprint Impact of bleeding severity on clinical outcomes among patients with acute coronary syndromes
    Sunil V Rao
    The Duke Clinical Research Institute, Durham, North Carolina, USA
    Am J Cardiol 96:1200-6. 2005
    ..Therapies that minimize bleeding risk and maintain an anticoagulant effect may improve outcomes among patients who have ACS...
  61. ncbi request reprint A comparison of the clinical impact of bleeding measured by two different classifications among patients with acute coronary syndromes
    Sunil V Rao
    Duke Clinical Research Institute, Durham, North Carolina 27715, USA
    J Am Coll Cardiol 47:809-16. 2006
    ..The goal of this study was to determine the association between Thrombolysis In Myocardial Infarction (TIMI) and Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) bleeding and clinical outcomes...
  62. doi request reprint Influence of body mass index on the efficacy of revascularization in patients with coronary artery disease
    Aslan T Turer
    Department of Medicine, Division of Cardiology, Duke University Medical Center, Durham, NC 27710, USA
    J Thorac Cardiovasc Surg 137:1468-74. 2009
    ..We examined the effect of body mass index on the association between revascularization strategy and survival in patients with coronary artery disease...
  63. ncbi request reprint The evaluation and management of dyslipidemia and impaired glucose metabolism during acute coronary syndromes
    Abhinav Goyal
    Duke University Medical Center, Duke Clinical Research Institute, 2400 Pratt Street, Durham, NC 27715, USA
    Curr Cardiol Rep 6:300-7. 2004
    ....
  64. ncbi request reprint Comparing classifications of death in the Mode Selection Trial: agreement and disagreement among site investigators and a clinical events committee
    John L Petersen
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27710, USA
    Contemp Clin Trials 27:260-8. 2006
    ..These findings support continued use of CECs for endpoint adjudication in clinical trials...
  65. ncbi request reprint Prognostic significance of the change in glucose level in the first 24 h after acute myocardial infarction: results from the CARDINAL study
    Abhinav Goyal
    Duke Clinical Research Institute and Duke University Medical Center, PO Box 17969, Durham, NC 27715, USA
    Eur Heart J 27:1289-97. 2006
    ..We evaluated the prognostic significance of baseline glucose and the change in glucose in the first 24 h following AMI...
  66. ncbi request reprint Integrating antithrombin and antiplatelet therapies with early invasive management for non-ST-segment elevation acute coronary syndromes
    Abdallah G Rebeiz
    Duke Clinical Research Institute and Division of Cardiology, Duke University Medical Center, Durham, North Carolina 27715, USA
    Am J Med 116:119-29. 2004
    ..We review the current evidence regarding the optimal integration of early antithrombotic and antiplatelet therapies with early coronary angiography and subsequent revascularization...
  67. ncbi request reprint Prognostic importance of new small Q waves following non-ST-elevation acute coronary syndromes
    John H Alexander
    Duke Clinical Research Institute, Durham, North Carolina 27710, USA
    Am J Med 115:613-9. 2003
    ..To investigate the prognostic importance of new small Q waves following an acute coronary syndrome...
  68. ncbi request reprint Statin use and sex-specific stroke outcomes in patients with vascular disease
    Cheryl D Bushnell
    Center for Cerebrovascular Disease, Duke University Medical Center, Durham, NC 27710, USA
    Stroke 37:1427-31. 2006
    ..We investigated the relationships between statin use and sex-specific stroke incidence, severity, and mortality...
  69. ncbi request reprint Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction: the COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) trial
    Christopher B Granger
    Duke Clinical Research Institute, PO Box 17969, Durham, NC 27715, USA
    Circulation 108:1184-90. 2003
    ....
  70. ncbi request reprint Experience with glycoprotein IIb/IIIa antagonists in patients with acute coronary syndromes
    David E Kandzari
    Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina 27710, USA
    J Interv Cardiol 15:121-9. 2002
  71. ncbi request reprint A perspective on trials comparing enoxaparin and unfractionated heparin in the treatment of non-ST-elevation acute coronary syndromes
    Robert M Califf
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27705, USA
    Am Heart J 149:S91-9. 2005
    ..Contemporary guidelines from the American College of Cardiology/American Heart Association call for use of low-molecular-weight heparin or unfractionated heparin (UFH)...
  72. doi request reprint Comparison of site-reported and core laboratory-reported creatine kinase-MB values in non-ST-segment elevation acute coronary syndrome (from the international trial SYNERGY)
    Jason P Linefsky
    Duke Clinical Research Institute, Durham, North Carolina, USA
    Am J Cardiol 104:1330-5. 2009
    ..More MI outcomes were identified by the core laboratory, and patients with MI as defined by core laboratory data had lower 1-year survival, making these events potentially clinically important...
  73. ncbi request reprint Rationale and strategies for implementing community-based transfer protocols for primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction
    Richard E Waters
    Duke University Medical Center and Duke Clinical Research Institute, Durham, North Carolina, USA
    J Am Coll Cardiol 43:2153-9. 2004
    ..Consequently, this current evolution of reperfusion strategies has the potential to further reduce morbidity and mortality for patients presenting with STEMI...
  74. ncbi request reprint Evaluation of Cinacalcet Therapy to Lower Cardiovascular Events (EVOLVE): rationale and design overview
    Glenn M Chertow
    Department of Medicine, University of California at San Francisco, San Francisco, California, USA
    Clin J Am Soc Nephrol 2:898-905. 2007
    ..However, no prospective trials have evaluated whether interventions that modify these laboratory parameters result in a reduction in adverse cardiovascular outcomes...
  75. ncbi request reprint Publication or presentation of results from multicenter clinical trials: evidence from an academic medical center
    Aslan T Turer
    Division of Cardiology, Department of Medicine, Duke University Medical Center, Durham, NC, USA
    Am Heart J 153:674-80. 2007
    ..We sought to examine rates of publication or presentation of research findings from multicenter clinical trials and determine what factors are associated with dissemination of results...
  76. ncbi request reprint Prognosis of patients taking selective serotonin reuptake inhibitors before coronary artery bypass grafting
    Glen L Xiong
    Department of Internal Medicine, Duke University Medical Center, Durham, North Carolina, USA
    Am J Cardiol 98:42-7. 2006
    ..26 to 1.70, p <0.0001, respectively). In conclusion, SSRI use before CABG was associated with a higher risk of long-term post-CABG mortality and rehospitalization. The explanation behind these findings requires further research...
  77. ncbi request reprint Troponin T levels in patients with acute coronary syndromes, with or without renal dysfunction
    Ronnier J Aviles
    Department of Cardiology, The Cleveland Clinic Foundation, Cleveland, OH 44951, USA
    N Engl J Med 346:2047-52. 2002
    ..However, there is concern that renal dysfunction may impair the prognostic value, because cardiac troponin T may be cleared by the kidney...
  78. ncbi request reprint Grade III ischemia on presentation with acute myocardial infarction predicts rapid progression of necrosis and less myocardial salvage with thrombolysis
    Yochai Birnbaum
    Division of Cardiology, University of Texas Medical Branch, Galveston, Tex 77555 0553, USA
    Cardiology 97:166-74. 2002
    ..045). Infarct size related to baseline ischemia grade and was reduced by adenosine treatment. Necrosis progressed slowlier with baseline grade II versus III ischemia, which could offer more time for myocardial salvage with reperfusion...
  79. ncbi request reprint Promise of combined low-molecular-weight heparin and platelet glycoprotein IIb/IIIa inhibition: results from Platelet IIb/IIIa Antagonist for the Reduction of Acute coronary syndrome events in a Global Organization Network B (PARAGON B)
    Debabrata Mukherjee
    University of Michigan Health System, Ann Arbor, Mich, USA
    Am Heart J 144:995-1002. 2002
    ..Minimal data are available on LMWH combined with platelet glycoprotein (GP) IIb/IIIa inhibitors...
  80. ncbi request reprint Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial
    James J Ferguson
    JAMA 292:45-54. 2004
    ..Enoxaparin has demonstrated advantages over unfractionated heparin in low- to moderate-risk patients with non-ST-segment elevation acute coronary syndromes (ACS) treated with a conservative strategy...
  81. ncbi request reprint Concerning the mechanism of pexelizumab's benefit in acute myocardial infarction
    Paul W Armstrong
    The University of Alberta, Edmonton, Alberta, Canada
    Am Heart J 151:787-90. 2006
    ....
  82. ncbi request reprint Heart failure on admission and the risk of stroke following acute myocardial infarction: the VALIANT registry
    Karolina E Szummer
    Department of Cardiology, Karolinska University Hospital Huddinge, Stockholm, Sweden
    Eur Heart J 26:2114-9. 2005
    ..We sought to assess the relative contribution of heart failure (HF) on admission for an acute myocardial infarction (MI) to the subsequent in-hospital stroke risk...
  83. ncbi request reprint Utilization of catheterization and revascularization procedures in patients with non-ST segment elevation acute coronary syndrome over the last decade
    Glenn N Levine
    Baylor College of Medicine and the Houston VA Medical Center, Houston, Texas 77030, USA
    Catheter Cardiovasc Interv 66:149-57. 2005
    ..The percentages of patients undergoing invasive and revascularization procedures were consistently higher in the U.S. cohorts of study subjects when compared to non-U.S. cohorts of study subjects...
  84. ncbi request reprint Bleeding complications in patients with acute coronary syndrome undergoing early invasive management can be reduced with radial access, smaller sheath sizes, and timely sheath removal
    Warren J Cantor
    Division of Cardiology, St Michael s Hospital, University of Toronto, Toronto, Ontario, Canada
    Catheter Cardiovasc Interv 69:73-83. 2007
    ..Our objective was to analyze the impact of arterial access site, sheath size, timing of sheath removal, and use of access site closure devices on high-risk patients with acute coronary syndromes (ACS)...
  85. ncbi request reprint The scientific community's quest to identify optimal targets for anticoagulant pharmacotherapy
    Kenneth W Mahaffey
    Circulation 114:2313-6. 2006
  86. ncbi request reprint Optimal timing for use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: questions, answers, and more questions
    Kenneth W Mahaffey
    JAMA 297:636-9. 2007
  87. ncbi request reprint A subgroup analysis of the impact of prerandomization antithrombin therapy on outcomes in the SYNERGY trial: enoxaparin versus unfractionated heparin in non-ST-segment elevation acute coronary syndromes
    Marc Cohen
    HEART Hospital of New Jersey, Newark Beth Israel Medical Center, Newark, New Jersey 07112, USA
    J Am Coll Cardiol 48:1346-54. 2006
    ....
  88. ncbi request reprint Baseline glucose and left ventricular remodeling after acute myocardial infarction
    Jose C Nicolau
    Heart Institute InCor, University of Sao Paulo Medical School, Sao Paulo, SP, Brazil
    J Diabetes Complications 21:294-9. 2007
    ..In conclusion, baseline glucose is a powerful and independent predictor of LVE after AMI, which reinforces the importance of a tight glucose control during the initial phase of the disease...
  89. pmc N-terminal pro-brain natriuretic peptide and the timing, extent and mortality in ST elevation myocardial infarction
    Justin A Ezekowitz
    University of Alberta, Edmonton, Canada
    Can J Cardiol 22:393-7. 2006
    ....
  90. doi request reprint Patients with non-ST-elevation acute coronary syndromes undergoing coronary artery bypass grafting in the modern era of antithrombotic therapy
    Derek P Chew
    Flinders Medical Centre, South Australia, Adelaide, Australia
    Am Heart J 155:239-44. 2008
    ..We explored the clinical outcomes among high-risk patients undergoing CABG and the impact of modern pharmacology...
  91. doi request reprint Coronary artery bypass surgery in patients with acute coronary syndromes is difficult to predict
    Derek P Chew
    Flinders Medical Centre, Adelaide, Australia
    Am Heart J 155:841-7. 2008
    ..We assessed the ability to predict need for CABG from demographics known at the time of ACS presentation, using data from SYNERGY...
  92. ncbi request reprint Forecasting mortality: dynamic assessment of risk in ST-segment elevation acute myocardial infarction
    Wei Ching Chang
    Department of Medicine, University of Alberta, 2 51 Medical Sciences Building, Edmonton, Alberta, Canada T6G 2H7
    Eur Heart J 27:419-26. 2006
    ..To demonstrate the feasibility and clinical utility of developing dynamic risk assessment models for ST-segment elevation myocardial infarction (STEMI) patients...
  93. doi request reprint Smoking status and antithrombin therapy in patients with non-ST-segment elevation acute coronary syndrome
    Steve Leung
    University of Kentucky, Lexington, KY, USA
    Am Heart J 156:177-84. 2008
    ..Smoking remains a major public health issue. We investigated the incidence of smoking and outcomes in high-risk patients with acute coronary syndromes. Differences in treatment effect of antithrombin therapies were also investigated...
  94. ncbi request reprint Efficacy and safety of enoxaparin compared with unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention in the Superior Yield of the New Strategy of Enoxaparin, Revas
    Harvey D White
    Green Lane Cardiovascular Service, Auckland City Hospital, Auckland, New Zealand
    Am Heart J 152:1042-50. 2006
    ..The SYNERGY trial compared these agents in high-risk patients undergoing early invasive treatment. Enoxaparin was noninferior to UFH for the 30-day primary end point of death/myocardial infarction (MI), but modestly increased bleeding...
  95. ncbi request reprint Electrocardiographic infarct size assessment after thrombolysis: insights from the Acute Myocardial Infarction STudy ADenosine (AMISTAD) trial
    Alejandro Barbagelata
    Hospital Italiano, Buenos Aires, Argentina
    Am Heart J 150:659-65. 2005
    ..The AMISTAD trial was analyzed to compare MI size and myocardial salvage determined by electrocardiogram (ECG) with technetium Tc 99m sestamibi single-photon emission computerized tomography (SPECT) imaging...
  96. doi request reprint ST-segment recovery and outcome after primary percutaneous coronary intervention for ST-elevation myocardial infarction: insights from the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) trial
    Christopher E Buller
    Vancouver General Hospital, University of British Columbia, Vancouver, British Columbia, Canada
    Circulation 118:1335-46. 2008
    ..Thus, we determined the prognostic importance of various measures of ST-segment-elevation recovery after primary PCI in a large, contemporary cohort of patients with ST-elevation myocardial infarction...
  97. doi request reprint Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial
    Gregg W Stone
    Columbia University Medical Center, The Cardiovascular Research Foundation, 111 E 59th St, 11th Floor, New York, NY 10022, USA
    JAMA 299:1903-13. 2008
    ....